IM Cannabis (IMCC) investor relations material

Company overview and business model

• International medical cannabis operations focused on Israel: product sourcing, imports, distribution and sales to pharmacies and other authorized distributors; relies mainly on imported products rather than large-scale local cultivation.

• Retail operations include Vironna Pharm and Pharm Yarok, plus Pharm Yarok’s online platform, customer service center and home delivery; retail activity also supports distribution and provides patient purchasing insights.

• Germany-focused operations were sold following a September 29, 2026 closing; the transaction consideration was C$3 million in advance payments, and resources are now focused on retained Israeli operations.

• Efficiency actions during 2024 and 2025 included logistics and workforce changes, facility closures, a new processing provider and operational adjustments for regional shipping disruptions.

Financial performance and metrics

• As of June 30, 2026, actual cash and cash equivalents were C$1.617 million, total assets C$24.692 million, total liabilities C$30.321 million and total equity deficit C$5.629 million.

• Pro forma as adjusted capitalization showed cash of C$8.777 million, total assets of C$20.940 million, total liabilities of C$16.831 million and total equity of C$4.109 million; adjustments include financings, the German business sale and assumed full note conversion and warrant exercise.

Use of proceeds and capital allocation

• US$1.02 million gross proceeds were received for the US$1.2 million initial promissory note; net proceeds are intended for general corporate purposes.

• No proceeds from selling registered shares go to the issuer; cash proceeds from any cash exercise of the warrant would be used for general corporate purposes.

• Beginning January 1, 2027, additional notes of up to US$1.2 million principal may be requested in each subsequent three-month period, subject to purchase-agreement conditions and an aggregate US$1.2 million subscription cap.